1. Home
  2. CRVS vs HELP Comparison

CRVS vs HELP Comparison

Compare CRVS & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$9.68

Market Cap

811.8M

Sector

Health Care

ML Signal

HOLD

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

HOLD

Current Price

$10.78

Market Cap

862.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRVS
HELP
Founded
2014
2019
Country
United States
Canada
Employees
37
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
811.8M
862.2M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
CRVS
HELP
Price
$9.68
$10.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
11
Target Price
$33.14
★ $40.33
AVG Volume (30 Days)
1.0M
★ 1.4M
Earning Date
11-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 48.04
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.39
$3.76
52 Week High
$26.95
$15.15

Technical Indicators

Market Signals
Indicator
CRVS
HELP
Relative Strength Index (RSI) 32.50 42.76
Support Level $6.39 $4.41
Resistance Level $13.73 $14.75
Average True Range (ATR) 0.58 0.82
MACD -0.04 -0.14
Stochastic Oscillator 17.38 22.53

Price Performance

Historical Comparison
CRVS
HELP

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: